secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001493152-23-042709
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD announces EFS agreement with Jacobs Institute for CGuard EPS in tandem lesion stroke patients
--------------------------------------------------------------------------------

- Agreement with Jacobs Institute to execute an Early Feasibility Study (EFS) of CGuard EPS for acute stroke with tandem lesions.
- EFS to enroll 15 patients across 3 U.S. sites; no FDA-approved stents currently exist for this indication.
- CGuard EPS features MicroNet mesh covering for embolic protection, low metal surface area to reduce thrombotic risk.
- CEO Marvin Slosman states tandem lesion indication is a critical component of long-term growth strategy.
- Dr. Siddiqui notes ~20% of acute strokes are tandem, and stenting in conjunction with thrombectomy may be superior.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/0001493152-23-042709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-042709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer